Tomáš Büchler

5.8k total citations · 1 hit paper
201 papers, 2.9k citations indexed

About

Tomáš Büchler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tomáš Büchler has authored 201 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Oncology, 85 papers in Pulmonary and Respiratory Medicine and 66 papers in Molecular Biology. Recurrent topics in Tomáš Büchler's work include Renal cell carcinoma treatment (44 papers), Colorectal Cancer Treatments and Studies (37 papers) and Cancer Genomics and Diagnostics (33 papers). Tomáš Büchler is often cited by papers focused on Renal cell carcinoma treatment (44 papers), Colorectal Cancer Treatments and Studies (37 papers) and Cancer Genomics and Diagnostics (33 papers). Tomáš Büchler collaborates with scholars based in Czechia, Italy and United States. Tomáš Büchler's co-authors include Pavel Vodička, Veronika Vymetálková, Soňa Vodenková, Klára Červená, Veronika Veškrňová, Alexandr Poprach, Bohuslav Melichar, Roman Hájek, Ladislav Dušek and Rostislav Vyzula and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Tomáš Büchler

182 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

2019 693 citations Soňa Vodenková, Tomáš Büchler et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomáš Büchler Czechia	26	1.4k	1.1k	741	720	387	201	2.9k
Jill Kolesar United States	37	2.0k 1.5×	1.8k 1.7×	936 1.3×	620 0.9×	243 0.6×	192	4.3k
Pierosandro Tagliaferri Italy	34	1.1k 0.8×	1.7k 1.6×	449 0.6×	615 0.9×	282 0.7×	97	3.2k
Jae Hong Seo South Korea	27	859 0.6×	1.6k 1.5×	523 0.7×	818 1.1×	190 0.5×	142	3.1k
Takashi Kijima Japan	26	1.3k 0.9×	1.4k 1.3×	1.2k 1.6×	320 0.4×	250 0.6×	167	3.4k
Tong Sun China	33	1.9k 1.3×	703 0.7×	581 0.8×	1.2k 1.6×	339 0.9×	95	3.4k
Gerald W. Prager Austria	32	1.0k 0.7×	1.7k 1.6×	802 1.1×	921 1.3×	243 0.6×	171	3.5k
Jong Gwang Kim South Korea	33	1.1k 0.8×	1.5k 1.4×	769 1.0×	590 0.8×	548 1.4×	203	3.4k
Gregory D. Ayers United States	28	961 0.7×	792 0.7×	317 0.4×	401 0.6×	227 0.6×	55	2.7k
Xiaohong Han China	27	899 0.6×	1.1k 1.0×	674 0.9×	405 0.6×	148 0.4×	183	2.7k
Gurkamal Chatta United States	34	1.2k 0.8×	1.3k 1.2×	1.0k 1.4×	450 0.6×	277 0.7×	143	3.5k

Countries citing papers authored by Tomáš Büchler

Since Specialization

Citations

This map shows the geographic impact of Tomáš Büchler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Büchler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Büchler more than expected).

Fields of papers citing papers by Tomáš Büchler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Büchler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Büchler. The network helps show where Tomáš Büchler may publish in the future.

Co-authorship network of co-authors of Tomáš Büchler

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Büchler. A scholar is included among the top collaborators of Tomáš Büchler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Büchler. Tomáš Büchler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Svobodník, Adam, et al.. (2025). Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer. PubMed. 2025(1). 1468262–1468262.

Naccarati, Alessio, Mihnea P. Dragomir, Sonia Tarallo, et al.. (2024). Fecal miRNA profiles in colorectal cancers with mucinous morphology. Mutagenesis. 40(1). 71–79. 3 indexed citations

Bartolini, Robin, Lily Koumbas Foley, Dmitry Stakheev, et al.. (2024). Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma. Translational Oncology. 42. 101891–101891. 1 indexed citations

Palmieri, Lola‐Jade, Tomáš Büchler, Antoine Meyer, et al.. (2022). Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. Cancers. 14(6). 1410–1410.

Fiala, Ondřej, Pavel Ostašov, Milan Hora, et al.. (2021). Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib. Cancer Management and Research. Volume 13. 4077–4086. 6 indexed citations

Büchler, Tomáš, et al.. (2021). Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases. Current Oncology. 28(5). 3403–3407. 11 indexed citations

Novakova-Jiresova, Alena, Kateřina Kopečková, Ludmila Boublíková, et al.. (2020). Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. SHILAP Revista de lepidopterología. 1 indexed citations

Büchler, Tomáš, Igor Kišš, Ondřej Fiala, et al.. (2020). Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology. 15(2). 193–201. 2 indexed citations

Novakova-Jiresova, Alena, Kateřina Kopečková, Ludmila Boublíková, et al.. (2020). <p>Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients</p>. Cancer Management and Research. Volume 12. 5365–5372. 9 indexed citations

10.

Poprach, Alexandr, Radek Lakomý, Michal Staník, et al.. (2019). Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. Urologic Oncology Seminars and Original Investigations. 37(4). 294.e1–294.e8. 5 indexed citations

11.

Jirásková, Kateřina, David J. Hughes, Stefanie Brezina, et al.. (2018). Functional Polymorphisms in DNA Repair Genes Are Associated with Sporadic Colorectal Cancer Susceptibility and Clinical Outcome. International Journal of Molecular Sciences. 20(1). 97–97. 21 indexed citations

12.

Vodenková, Soňa, Kateřina Jirásková, Markéta Urbanová, et al.. (2018). Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients. DNA repair. 72. 77–85. 27 indexed citations

13.

Büchler, Tomáš, Alexandr Poprach, Ondřej Fiala, et al.. (2018). Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Management and Research. Volume 11. 359–368. 8 indexed citations

14.

Büchler, Tomáš, Vladimír Bobek, & Katarína Kološtová. (2018). AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer. Klinicka onkologie. 31(1). 9–14. 1 indexed citations

15.

Poprach, Alexandr, Radek Lakomý, & Tomáš Büchler. (2017). Immunotherapy of Renal Cell Carcinoma. Klinicka onkologie. 30(Suppl 3). 3S55–3S61. 10 indexed citations

16.

Poprach, Alexandr, Radek Lakomý, Zbyněk Bortlíček, et al.. (2016). Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging. 33(9). 655–663. 15 indexed citations

17.

Poprach, Alexandr, Zbyněk Bortlíček, Bohuslav Melichar, et al.. (2015). Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer. 51(4). 507–513. 10 indexed citations

18.

Kubáčková, Kateřina, Zbyněk Bortlíček, Tomáš Pavlík, et al.. (2014). Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Targeted Oncology. 10(3). 385–392. 6 indexed citations

19.

Büchler, Tomáš, Zbyněk Bortlíček, Alexandr Poprach, et al.. (2014). Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. Urologic Oncology Seminars and Original Investigations. 32(5). 569–575. 12 indexed citations

20.

Pardini, Barbara, Fabio Rosa, Elisa Barone, et al.. (2013). Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding. Clinical Cancer Research. 19(21). 6044–6056. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact